Report Detail
Global Osteoporosis Drugs Market Insights, Forecast to 2025
- RnM2799875 |
- 25 February, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis Drugs is a kind of medicine for Osteoporosis, such as Fosamax, Actonel, Boniva, Zoledronic Acid (Reclast or Zometa) and others.
Osteoporosis, which literally means porous bone, is a disease in which the density and quality of bone are reduced. As bones become more porous and fragile, the risk of fracture is greatly increased. The loss of bone occurs silently and progressively. Often there are no symptoms until the first fracture occurs. Osteoporosis drugs are a kind of medicine for Osteoporosis. The types of osteoporosis drugs mainly include antiresorptive drugs and anabolic drugs.
The Brazil osteoporosis drugs is Very concentrated, the sales of top eight manufacturers account exceeds 70% of Brazil sales.
The antiresorptive drugs is the main types of osteoporosis drugs. In 2015, the sales revenue of antiresorptive drugs is about 109 M USD; its proportion of total osteoporosis drugs exceeds 73%.
The global Osteoporosis Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Osteoporosis Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Osteoporosis Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Osteoporosis Drugs in these regions.
This research report categorizes the global Osteoporosis Drugs market by top players/brands, region, type and end user. This report also studies the global Osteoporosis Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche
Market size by Product
Antiresorptive Drugs
Anabolic Drugs
Market size by End User
Female
Male
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Osteoporosis Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Osteoporosis Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Osteoporosis Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Osteoporosis Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Osteoporosis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Osteoporosis Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Osteoporosis Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Osteoporosis Drugs Market Size Growth Rate by Product
- 1.4.2 Antiresorptive Drugs
- 1.4.3 Anabolic Drugs
- 1.5 Market by End User
- 1.5.1 Global Osteoporosis Drugs Market Size Growth Rate by End User
- 1.5.2 Female
- 1.5.3 Male
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Osteoporosis Drugs Market Size
- 2.1.1 Global Osteoporosis Drugs Revenue 2014-2025
- 2.1.2 Global Osteoporosis Drugs Sales 2014-2025
- 2.2 Osteoporosis Drugs Growth Rate by Regions
- 2.2.1 Global Osteoporosis Drugs Sales by Regions
- 2.2.2 Global Osteoporosis Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Osteoporosis Drugs Sales by Manufacturers
- 3.1.1 Osteoporosis Drugs Sales by Manufacturers
- 3.1.2 Osteoporosis Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Osteoporosis Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Osteoporosis Drugs Revenue by Manufacturers
- 3.2.1 Osteoporosis Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Osteoporosis Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Osteoporosis Drugs Price by Manufacturers
- 3.4 Osteoporosis Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Osteoporosis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Osteoporosis Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Osteoporosis Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Osteoporosis Drugs Sales by Product
- 4.2 Global Osteoporosis Drugs Revenue by Product
- 4.3 Osteoporosis Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Osteoporosis Drugs Breakdown Data by End User
6 North America
- 6.1 North America Osteoporosis Drugs by Countries
- 6.1.1 North America Osteoporosis Drugs Sales by Countries
- 6.1.2 North America Osteoporosis Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Osteoporosis Drugs by Product
- 6.3 North America Osteoporosis Drugs by End User
7 Europe
- 7.1 Europe Osteoporosis Drugs by Countries
- 7.1.1 Europe Osteoporosis Drugs Sales by Countries
- 7.1.2 Europe Osteoporosis Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Osteoporosis Drugs by Product
- 7.3 Europe Osteoporosis Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Osteoporosis Drugs by Countries
- 8.1.1 Asia Pacific Osteoporosis Drugs Sales by Countries
- 8.1.2 Asia Pacific Osteoporosis Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Osteoporosis Drugs by Product
- 8.3 Asia Pacific Osteoporosis Drugs by End User
9 Central & South America
- 9.1 Central & South America Osteoporosis Drugs by Countries
- 9.1.1 Central & South America Osteoporosis Drugs Sales by Countries
- 9.1.2 Central & South America Osteoporosis Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Osteoporosis Drugs by Product
- 9.3 Central & South America Osteoporosis Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Osteoporosis Drugs by Countries
- 10.1.1 Middle East and Africa Osteoporosis Drugs Sales by Countries
- 10.1.2 Middle East and Africa Osteoporosis Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Osteoporosis Drugs by Product
- 10.3 Middle East and Africa Osteoporosis Drugs by End User
11 Company Profiles
- 11.1 Eli Lilly
- 11.1.1 Eli Lilly Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Eli Lilly Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Eli Lilly Osteoporosis Drugs Products Offered
- 11.1.5 Eli Lilly Recent Development
- 11.2 Novartis
- 11.2.1 Novartis Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Novartis Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Novartis Osteoporosis Drugs Products Offered
- 11.2.5 Novartis Recent Development
- 11.3 Pfizer
- 11.3.1 Pfizer Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Pfizer Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Pfizer Osteoporosis Drugs Products Offered
- 11.3.5 Pfizer Recent Development
- 11.4 Amgen
- 11.4.1 Amgen Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Amgen Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Amgen Osteoporosis Drugs Products Offered
- 11.4.5 Amgen Recent Development
- 11.5 Merck
- 11.5.1 Merck Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Merck Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Merck Osteoporosis Drugs Products Offered
- 11.5.5 Merck Recent Development
- 11.6 Novo nordisk
- 11.6.1 Novo nordisk Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Novo nordisk Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Novo nordisk Osteoporosis Drugs Products Offered
- 11.6.5 Novo nordisk Recent Development
- 11.7 Actavis
- 11.7.1 Actavis Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Actavis Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Actavis Osteoporosis Drugs Products Offered
- 11.7.5 Actavis Recent Development
- 11.8 Roche
- 11.8.1 Roche Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Roche Osteoporosis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Roche Osteoporosis Drugs Products Offered
- 11.8.5 Roche Recent Development
12 Future Forecast
- 12.1 Osteoporosis Drugs Market Forecast by Regions
- 12.1.1 Global Osteoporosis Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Osteoporosis Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Osteoporosis Drugs Market Forecast by Product
- 12.2.1 Global Osteoporosis Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Osteoporosis Drugs Revenue Forecast by Product 2019-2025
- 12.3 Osteoporosis Drugs Market Forecast by End User
- 12.4 North America Osteoporosis Drugs Forecast
- 12.5 Europe Osteoporosis Drugs Forecast
- 12.6 Asia Pacific Osteoporosis Drugs Forecast
- 12.7 Central & South America Osteoporosis Drugs Forecast
- 12.8 Middle East and Africa Osteoporosis Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Osteoporosis Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Osteoporosis Drugs . Industry analysis & Market Report on Osteoporosis Drugs is a syndicated market report, published as Global Osteoporosis Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Osteoporosis Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
